Kobayashi Pharmaceutical Co., Ltd. (KBYPF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) trades at $34.05 with AI Score 50/100 (Grade B). Kobayashi Pharmaceutical Co. , Ltd. Market cap: $2.53B, Sector: Consumer defensive.
Last analyzed: Mar 16, 2026Analyst Coverage for KBYPF: KBYPF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KBYPF against Consumer Defensive peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KBYPF: 3/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) Consumer Business Overview
Kobayashi Pharmaceutical Co., Ltd. is a global consumer products company specializing in healthcare, household, skincare, and body warmer products. With a history dating back to 1886, the company offers a diverse portfolio of well-established brands and operates in both domestic and international markets, maintaining a presence in the consumer defensive sector.
What Is the Investment Thesis for KBYPF?
Kobayashi Pharmaceutical Co., Ltd. presents a stable investment opportunity within the consumer defensive sector. The company's diverse product portfolio and established brands provide a degree of resilience against economic downturns. With a dividend yield of 1.85% and a beta of 0.32, the stock offers a combination of income and low volatility. However, a high P/E ratio of 114.52 and a low profit margin of 2.2% raise concerns about valuation and profitability. Growth catalysts include expansion into new international markets and the introduction of innovative products. Potential risks include increasing competition and changing consumer preferences. Investors should carefully consider the company's financial metrics and growth prospects before making an investment decision.
Based on FMP financials and quantitative analysis
KBYPF Key Highlights
- Market capitalization of $2.53 billion indicates a mid-sized company within the consumer defensive sector.
- P/E ratio of 114.52 suggests a high valuation relative to earnings, potentially indicating overvaluation or high growth expectations.
- Gross margin of 51.1% reflects the company's ability to manage production costs and maintain pricing power.
- Dividend yield of 1.85% provides a moderate income stream for investors.
- Beta of 0.32 indicates low volatility compared to the overall market, making it a potentially stable investment.
Who Are KBYPF's Competitors?
KBYPF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BICEF Société BIC S.A. | $63.29 | -7.00% | $2.57B | 46 |
| BLUMY Blue Moon Group Holdings Limited | $1.78 | +0.00% | $2.01B | 53 |
| KNKZF KWS SAAT SE & Co. KGaA | $84.83 | +0.00% | $2.80B | 57 |
| KSRYY KOSÉ Corporation | $6.22 | -3.34% | $1.77B | 53 |
| LIOPF Lion Corporation | $11.51 | +0.00% | $3.18B | 54 |
| FACYF Fancl Corporation | $17.45 | +0.00% | $2.37B | 63 |
| SGI Somnigroup International Inc | $72.67 | +0.48% | $15.28B | 62 |
| ELF e.l.f. Beauty, Inc. | $60.68 | +4.40% | $3.61B | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KBYPF's Key Strengths?
- Strong brand reputation in Japan and Asia.
- Diverse product portfolio across multiple consumer segments.
- Established distribution network.
- Consistent investment in research and development.
What Are KBYPF's Weaknesses?
- High P/E ratio compared to industry peers.
- Low profit margin.
- Limited presence in Western markets.
- Dependence on the Japanese market.
What Could Drive KBYPF Stock Higher?
- Potential expansion into new international markets, particularly in Southeast Asia and Latin America.
- Continuous investment in research and development to create innovative products.
- Growing consumer focus on health and wellness trends, driving demand for related products.
- Strategic acquisitions to expand product portfolio and enter new markets.
What Are the Key Risks for KBYPF?
- Increasing competition from multinational corporations in the consumer products industry.
- Changing consumer preferences and trends, requiring continuous adaptation.
- Fluctuations in currency exchange rates, impacting international sales and profitability.
- High P/E ratio compared to industry peers, suggesting potential overvaluation.
- Limited financial disclosure due to OTC listing.
What Are the Growth Opportunities for KBYPF?
- Expansion into Emerging Markets: Kobayashi Pharmaceutical has the opportunity to expand its presence in emerging markets, particularly in Southeast Asia and Latin America. These regions offer significant growth potential due to increasing disposable incomes and a growing demand for consumer products. By adapting its product offerings to local preferences and establishing strategic partnerships, Kobayashi Pharmaceutical can tap into these markets and drive revenue growth. The market size for consumer products in emerging markets is estimated to reach $1.4 trillion by 2028, presenting a substantial opportunity for the company.
- New Product Development: Kobayashi Pharmaceutical can drive growth through continuous innovation and the development of new products that address unmet consumer needs. By investing in research and development, the company can create innovative solutions in areas such as healthcare, skincare, and household products. The launch of new products can attract new customers and increase market share. The global market for new consumer products is estimated at $500 billion annually, providing a significant opportunity for Kobayashi Pharmaceutical to capitalize on innovation.
- Strategic Acquisitions: Kobayashi Pharmaceutical can pursue strategic acquisitions to expand its product portfolio, enter new markets, and gain access to new technologies. By acquiring companies with complementary products or technologies, Kobayashi Pharmaceutical can accelerate its growth and strengthen its competitive position. The company can target acquisitions in areas such as skincare, health supplements, and household cleaning products. The market for mergers and acquisitions in the consumer products industry is active, with deal values reaching $200 billion in 2025.
- E-commerce Expansion: Kobayashi Pharmaceutical can leverage the growth of e-commerce to expand its reach and increase sales. By investing in its online platforms and partnering with e-commerce retailers, the company can reach a wider audience and offer its products directly to consumers. E-commerce provides a cost-effective way to enter new markets and increase brand awareness. The global e-commerce market is projected to reach $7.4 trillion by 2025, presenting a significant opportunity for Kobayashi Pharmaceutical to expand its online presence.
- Focus on Health and Wellness Trends: Kobayashi Pharmaceutical can capitalize on the growing consumer focus on health and wellness by developing and marketing products that promote healthy lifestyles. This includes products such as health supplements, skincare products with natural ingredients, and functional foods. By aligning its product offerings with health and wellness trends, Kobayashi Pharmaceutical can attract health-conscious consumers and drive revenue growth. The global health and wellness market is estimated to reach $7 trillion by 2025, providing a substantial opportunity for the company.
What Opportunities Does KBYPF Have?
- Expansion into emerging markets.
- Development of new products targeting health and wellness trends.
- Strategic acquisitions to expand product portfolio.
- Increased focus on e-commerce and online sales channels.
What Threats Does KBYPF Face?
- Increasing competition from multinational corporations.
- Changing consumer preferences and trends.
- Fluctuations in currency exchange rates.
- Regulatory changes in the pharmaceutical and consumer products industries.
What Are KBYPF's Competitive Advantages?
- Strong brand recognition and reputation in Japan and other Asian markets.
- Diverse product portfolio catering to a wide range of consumer needs.
- Established distribution network and relationships with retailers.
- Continuous investment in research and development to create innovative products.
What Does KBYPF Do?
Founded in 1886, Kobayashi Pharmaceutical Co., Ltd. has evolved from a small pharmaceutical manufacturer into a diversified consumer products company. Headquartered in Osaka, Japan, the company's initial focus was on developing and marketing innovative healthcare solutions. Over the years, Kobayashi Pharmaceutical expanded its product lines to include household products, skincare items, and body warmers, catering to a wide range of consumer needs. The company's growth strategy has involved both organic product development and strategic acquisitions, allowing it to build a strong portfolio of well-known brands. Kobayashi Pharmaceutical's product offerings include topical analgesics like Ammeltz, women's health medicines such as Inochi no Haha, and oral hygiene products like BreathCare. The company also provides household cleaning solutions, skincare products, and health supplements. Kobayashi Pharmaceutical distributes its products through various channels, including retail stores, online platforms, and direct sales. With a global presence, the company operates in multiple international markets, adapting its product offerings to meet local consumer preferences and regulatory requirements. Kobayashi Pharmaceutical continues to focus on innovation and quality, aiming to provide consumers with effective and reliable products that enhance their daily lives.
What Products and Services Does KBYPF Offer?
- Manufactures and sells healthcare products, including topical analgesics and women's health medicines.
- Produces and distributes household products such as toilet bowl cleaners and air fresheners.
- Develops and markets skincare products, including medicated lotions and cleansers.
- Offers body warmers for cold weather and therapeutic purposes.
- Manufactures and sells pharmaceuticals and quasi-drugs.
- Markets nutritional supplements and health foods.
- Engages in real estate management and asset management.
How Does KBYPF Make Money?
- Develops, manufactures, and markets a wide range of consumer products.
- Distributes products through retail stores, online platforms, and direct sales channels.
- Generates revenue through the sale of its products to consumers and retailers.
- Invests in research and development to create innovative products.
What Industry Does KBYPF Operate In?
Kobayashi Pharmaceutical Co., Ltd. operates in the competitive household and personal products industry, which is characterized by stable demand and a focus on innovation. The market is driven by consumer spending patterns, demographic trends, and health awareness. Key players in the industry include multinational corporations and regional brands, all vying for market share. Kobayashi Pharmaceutical differentiates itself through its focus on niche product categories and its strong brand reputation in Japan and other Asian markets. The company faces competition from both established players and emerging brands, requiring continuous investment in research and development to maintain its competitive edge.
Who Are KBYPF's Key Customers?
- Consumers seeking healthcare products for pain relief, women's health, and oral hygiene.
- Households looking for cleaning and air freshening solutions.
- Individuals seeking skincare products for acne prevention and general skincare.
- Consumers interested in health supplements and nutritional products.
KBYPF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, signaling potential undervaluation to some investors.
- Community sentiment reflects a belief in the long-term value of Kobayashi's established brands and market presence.
- Positive discussions within the community highlight the company's commitment to innovation and new product development.
- The market generally perceives Kobayashi as a stable and reliable player in the consumer healthcare sector.
Bear Case
- Recent negative press regarding product recalls has shaken community confidence and raised concerns about quality control.
- Some community members express worries about increased competition from both domestic and international players.
- Bearish sentiment points to potential challenges in maintaining market share and brand loyalty amid evolving consumer preferences.
- Market perception has been negatively impacted by recent supply chain disruptions, leading to concerns about product availability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
KBYPF Latest News
No recent news available for KBYPF.
KBYPF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KBYPF.
Price Targets
Wall Street price target analysis for KBYPF.
KBYPF MoonshotScore
What does this score mean?
The MoonshotScore rates KBYPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yumi Nakagawa
CEO
Yumi Nakagawa serves as the CEO of Kobayashi Pharmaceutical Co., Ltd., overseeing the company's global operations and strategic direction. Her background includes extensive experience in the consumer products industry, with a focus on marketing and product development. Prior to becoming CEO, she held various leadership positions within Kobayashi Pharmaceutical, including head of marketing and vice president of product innovation. Nakagawa holds a degree in business administration from a leading Japanese university.
Track Record: Under Yumi Nakagawa's leadership, Kobayashi Pharmaceutical has focused on expanding its presence in international markets and launching new innovative products. She has overseen the company's efforts to strengthen its brand reputation and improve its operational efficiency. Key milestones during her tenure include the successful launch of several new product lines and the expansion of the company's e-commerce presence.
KBYPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Kobayashi Pharmaceutical Co., Ltd. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure may make it difficult to assess the company's financial health.
- Lower trading volume can lead to price volatility and difficulty in buying or selling shares.
- Lack of regulatory oversight increases the risk of fraud or mismanagement.
- OTC stocks may be subject to delisting or trading suspensions.
- The OTC Other tier carries the highest level of risk among OTC markets.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Monitor trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making an investment decision.
- The company has been in business since 1886, indicating a long operating history.
- Kobayashi Pharmaceutical has a diverse product portfolio and established brands.
- The company has a global presence and operates in multiple international markets.
- Kobayashi Pharmaceutical is managed by an experienced CEO, Yumi Nakagawa.
Common Questions About KBYPF (Consumer Defensive)
What does Kobayashi Pharmaceutical Co., Ltd. do?
Kobayashi Pharmaceutical Co., Ltd. is a consumer products company that manufactures and sells a wide range of healthcare, household, skincare, and body warmer products. The company's product portfolio includes well-known brands such as Ammeltz, Inochi no Haha, and BreathCare. Kobayashi Pharmaceutical distributes its products through various channels, including retail stores, online platforms, and direct sales. The company operates in both domestic and international markets, catering to a diverse range of consumer needs. Kobayashi Pharmaceutical focuses on innovation and quality, aiming to provide consumers with effective and reliable products that enhance their daily lives.
What are the main risks for KBYPF?
The main risks for KBYPF include increasing competition from multinational corporations, changing consumer preferences, and fluctuations in currency exchange rates. The company's high P/E ratio also poses a risk, suggesting potential overvaluation. As an OTC-listed stock, KBYPF faces additional risks related to limited financial disclosure and lower trading volume. Investors should be aware of these risks and conduct thorough due diligence before investing in KBYPF. The OTC Other tier carries the highest level of risk among OTC markets, requiring careful consideration of the company's financial health and business prospects.
What are the key factors to evaluate for KBYPF?
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does KBYPF data refresh on this page?
KBYPF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KBYPF's recent stock price performance?
Kobayashi Pharmaceutical Co., Ltd. (KBYPF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong brand reputation in Japan and Asia. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KBYPF overvalued or undervalued right now?
Valuing Kobayashi Pharmaceutical Co., Ltd. (KBYPF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying KBYPF?
Before investing in Kobayashi Pharmaceutical Co., Ltd. (KBYPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding KBYPF to a portfolio?
Key strength of Kobayashi Pharmaceutical Co., Ltd. (KBYPF): Strong brand reputation in Japan and Asia. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data for exchange-listed stocks.